Sign up Australia
Proactive Investors - Run By Investors For Investors

Algae.Tec’s shares rise after licensing unique pharmaceutical delivery technology

Algae.Tec has signed a deal with a private Australian-based pharmaceutical delivery company.
a lab technician
Algae oil will be the base component

Algae.Tec Ltd’s (ASX:AEB) shares are trading circa 13% higher intra-day after licensing a patented mini emulsion-based delivery platform for pharmaceutical application.

The company has signed an agreement with a private Australian-based pharmaceutical delivery company, NS Technologies (NST) for the delivery platform technology.

Lower dosage with an effective outcome

The technology is one where a ‘mini-emulsion’ was developed to allow complex molecules to penetrate the epidermis skin layer, and enter the subdermal layer of the human body.

The mini-emulsion droplets filter through the epidermal layer, in an effective, “slow release” manner, allowing lower dosages, with an effective outcome.

This mini-emulsion base component requires a selected vegetable oil, which is ideally suited to specific algal oils.

Algae.Tec’s algal oils could be the base component

Under the agreement, Algae.Tec will acquire 19.9% of NST and exclusively license NST’s delivery platform technology for use across any medical application developed by Algae.Tec.

NST has also agreed to use AEB’s algae oil as the base component of its emulsion delivery platform.

The companies are aiming to develop a range of mini-emulsion pharmaceutical products for both human and veterinary purposes using selected algal oils.

READ: Algae.Tec to boost cash for medical cannabis cultivation plans

View full AEB profile View Profile

Algae.Tec Timeline

Related Articles

oil and gas operations
January 30 2018
Chief executive Matthew Idiens described the initial seismic results as “a watershed moment” for Rose
Greka drilling rig truck
January 29 2018
"With firm drilling contracts signed with state owned enterprises, we start 2018 with a materially stronger foundation than last year”
oil well
April 27 2018
A cash flow model - assuming one new IOsorb plant is added each year between 2019 and 2021 - gives a price target of 35p/share

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use